Street Calls of the Week
Reprogrammed Interchange LLC and Reid Hoffman, both listed as 10% owners of Vor Biopharma Inc (NASDAQ:VOR), have collectively sold 65,357 shares of common stock for approximately $3,003,705. The stock, which has shown significant volatility with a beta of 2.08, has surged over 115% in the past six months despite a recent 9.5% decline last week.
The sales occurred in multiple transactions between October 10 and October 14, 2025, with prices ranging from $30.3192 to $33.0873 per share. On October 10, 40,983 shares were sold. On October 13, 19,672 shares were sold, followed by 2,334 shares on the same day. The final transaction occurred on October 14, with 33,668 shares sold. Track insider trading patterns and get comprehensive analysis with InvestingPro, which offers 12 additional key insights about VOR’s financial health and market position.
Following these transactions, Reprogrammed Interchange LLC directly holds 1,278,118 shares of Vor Biopharma , representing a significant stake in the company, which currently has a market capitalization of $208 million.
In other recent news, Vor Biopharma has been in the spotlight due to several significant developments. The company, in collaboration with RemeGen, reported positive results from a Phase 3 study of telitacicept for primary Sjögren’s disease. The trial, conducted in China, met its primary and all secondary endpoints, with the telitacicept 160mg dose showing significant improvements compared to placebo. Following these promising results, Baird upgraded Vor Biopharma’s stock rating from Neutral to Outperform, citing the potential of telitacicept and raising the price target to $64.00 from $20.00.
Additionally, Vor Biopharma announced that it will present the Phase 3 clinical data at the ACR Convergence 2025 conference in Chicago. This presentation will highlight the significant findings from the multicenter, randomized, double-blind, placebo-controlled trial. In another development, Vor Biopharma filed a preliminary prospectus for the potential resale of up to 50,999,999 shares of its common stock by selling stockholders. This includes shares issuable upon exercise of outstanding warrants, involving a significant portion allocated to a subsidiary of RemeGen and other investors. These recent developments have attracted considerable attention from investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.